

Cover Story
Vitrakvi (larotrectinib) aims to treat a very small group of people—some say fewer than 3,000 new patients a year in the U.S. And since these patients have diseases that span multiple tumor sites, finding them isn't easy.
In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- Most NIH activities will cease immediately if government shuts down
- NCI braces for funding cuts, shutdown
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Women physicians are underrepresented in film, a study led by oncologists finds